To ensure that 192-IgG-saporin was not having a direct effect on the corneal surface itself, we applied 192-IgG-saporin topically to the corneal surface (without removal of tear film barrier) in a separate group of rats and measured eye wipe responses, tear production, and eye closures 3 weeks later. Rats that received topical saporin did not show any alterations in eye wipe responses to 50 mM menthol (topical saporin: 9.6 ± 1.5 eye wipes,
n = 5; control: 7.3 ± 1.2 eye wipes,
n = 4;
t-test,
P = 0.28). The data from the control animals were recently published as part of another study.
10 There were no changes in tear production 3 weeks after topical saporin application (topical saporin baseline: 10.7 ± 0.9 mm; 3-week endpoint: 12.7 ± 2.6 mm,
n = 3; paired
t-test,
P = 0.44). Eye closures were also assessed 3 weeks after topical saporin and compared with naïve control animals. There were no changes in total eye closures (blinks and winks) on the treated (left) side (topical saporin baseline: 6.0 ± 3.5 eye closures, 3-week endpoint: 6.7 ± 2.9 eye closures,
n = 3; control baseline: 3.8 ± 1.9 eye closures, control 3 weeks: 5.0 ± 0.7 eye closures,
n = 4; 2-way ANOVA,
P = 0.4). Unilateral winks on the treated side were also not altered when topical saporin was compared with controls (topical saporin baseline: 2.3 ± 1.9 winks, 3-week endpoint: 2.0 ± 0.6 winks,
n = 3; control baseline: 1.5 ± .9 winks, 3-week endpoint: 4.3 ± 1.4 winks,
n = 4; 2-way ANOVA,
P = 0.6). There were no changes in lacrimal gland weight after topical saporin (left: 134.5 ± 13.5 mg, right: 132.7 ± 10.8 mg,
n = 5;
t-test,
P = 0.9). These findings demonstrate that the alterations after saporin-induced denervation of the lacrimal gland were not due to a direct effect of the saporin toxin on the corneal surface.